Literature DB >> 10984324

Mechanisms of action and resistance of older and newer fluoroquinolones.

D C Hooper1.   

Abstract

The fluoroquinolones interact with 2 bacterial targets, the related enzymes DNA gyrase and topoisomerase IV, both of which are involved in DNA replication. Quinolones form complexes of these enzymes with DNA, complexes that block movement of the DNA-replication fork and thereby inhibit DNA replication. Many older quinolones differ in their relative activities against gyrase and topoisomerase IV in a bacterial cell, having greater potency against gyrase than against topoisomerase IV in many gram-negative bacteria and greater potency against topoisomerase IV than against gyrase in many gram-positive bacteria. Several newer quinolones appear to have more closely balanced activity against these enzymes. Resistance to fluoroquinolones occurs as a result of mutational amino acid substitutions in the subunits of the more sensitive (or primary-target) enzyme within the cell. If, however, both enzymes are similarly susceptible to a fluoroquinolone, then the level of resistance caused by a primary-target mutation may be low and may be limited by the sensitivity of the secondary target. Fluoroquinolones also differ in the extent to which common bacterial multidrug efflux pumps affect their activity, with some compounds being unaffected by resistance mechanisms because of overexpression of such pumps. Newer fluoroquinolone interaction with dual targets and avoidance of efflux-resistance mechanisms may each contribute to the lower frequencies of selection of resistant mutants in the laboratory.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10984324     DOI: 10.1086/314056

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  97 in total

1.  Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition.

Authors:  M Takei; H Fukuda; R Kishii; M Hosaka
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

2.  Comparative pharmacodynamics of three newer fluoroquinolones versus six strains of staphylococci in an in vitro model under aerobic and anaerobic conditions.

Authors:  David H Wright; Brent W Gunderson; Laurie B Hovde; Gigi H Ross; Khalid H Ibrahim; John C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

3.  Assessing sensitivity to antibacterial topoisomerase II inhibitors.

Authors:  Sonia K Morgan-Linnell; Hiroshi Hiasa; Lynn Zechiedrich; John L Nitiss
Journal:  Curr Protoc Pharmacol       Date:  2007-12

4.  The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins.

Authors:  Hsun-Cheng Su; Kevin Ramkissoon; Janet Doolittle; Martha Clark; Jainab Khatun; Ashley Secrest; Matthew C Wolfgang; Morgan C Giddings
Journal:  Antimicrob Agents Chemother       Date:  2010-08-09       Impact factor: 5.191

5.  Structural and biochemical analysis of the pentapeptide repeat protein EfsQnr, a potent DNA gyrase inhibitor.

Authors:  Subray S Hegde; Matthew W Vetting; Lesley A Mitchenall; Anthony Maxwell; John S Blanchard
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

6.  Effect of emergence of fluoroquinolone resistance on intrinsic expression of P-glycoprotein phenotype in corneal epithelial cells.

Authors:  Megha Barot; Mitan R Gokulgandhi; Megan Haghnegahdar; Pranjali Dalvi; Ashim K Mitra
Journal:  J Ocul Pharmacol Ther       Date:  2011-08-10       Impact factor: 2.671

7.  Extensively and pan-drug resistant Pseudomonas aeruginosa keratitis: clinical features, risk factors, and outcome.

Authors:  Merle Fernandes; Divya Vira; Radhika Medikonda; Nagendra Kumar
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-11-04       Impact factor: 3.117

8.  Mechanisms of reduced susceptibility to ciprofloxacin in Escherichia coli isolates from Canadian hospitals.

Authors:  Patricia J Baudry-Simner; Amanpreet Singh; James A Karlowsky; Daryl J Hoban; George G Zhanel
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

9.  Provider and health care system response to a bioterrorist attack.

Authors:  J D Malone
Journal:  Proc (Bayl Univ Med Cent)       Date:  2001-07

Review 10.  Multidrug resistance in bacteria.

Authors:  Hiroshi Nikaido
Journal:  Annu Rev Biochem       Date:  2009       Impact factor: 23.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.